A Phase 2b Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Enzastaurin (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Denovo Biopharma
- 13 Dec 2018 Status changed from not stated to not yet recruiting.
- 16 Oct 2006 New trial record.